# JOHNSON WINTER & SLATTERY

WYERS

Partner:

Damian Reichel (02) 8274 9530

Email:

damian.reichel@jws.com.au

Our Ref:

A5393

Doc ID:

61128579.1

15 February 2011

Company Announcements Platform

**ASX Limited** 

Level 4, 20 Bridge Street

SYDNEY NSW 2000

By facsimile: 1300 135 638

Mesoblast Limited

Level 39

55 Collins Street

**MELBOURNE VIC 3000** 

By facsimile: (03) 9639 6036

5 pages

Dear Sir/Madam

Cephalon International Holdings, Inc. – Notice of change of interests of substantial holder in relation to shares in Mesoblast Limited

We act for Cephalon, Inc., and its wholly owned subsidiary Cephalon International Holdings, Inc.

In accordance with section 671B(1)(b) of the Corporations Act 2001 (Cth), we attach a Form 604 (Notice of change of interests of substantial holder) by Cephalon International Holdings, Inc., Cephalon, Inc. and its related bodies corporate in relation to shares in Mesoblast Limited.

Yours faithfully

Winter & SlaH

Level 30, 264 George Street SYDNEY NSW 2000 T +61 2 8274 9555 | F +61 2 8274 9500

#### Form 604

To: 01300135638#193

#### Corporations Act 2001 Section 671B

# Notice of change of interests of substantial holder

To Company Name/Scheme Mesoblast Limited

ACN/ARSN

109 431 870

Name

1. Details of substantial holder (1)

Cephalon International Holdings, Inc., Cephalon, Inc. and each of the related bodies corporate of

Cephalon, inc. listed in Annexure A (Cephalon related bodies corporate)

ACN/ARSN (if applicable)

Not applicable

There was a change in the interests The previous notice was given to the 11 February 2011

of the substantial holder on

23 December 2010

company on

The previous notice was dated

23 December 2010

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

C	lass of securities (4)	Previous Notice		Present notice	Present notice	
		Person's votes	Voting power (5)	Person's votes	Voting power (5)	
	rdinary shares	31.083.750	12.2%	55,785,806	19.99%	

#### 3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of Chang	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
.11 February 2	011 Cephalon International Holdings, Inc.	Relevant interest under section 608(1) of the Corporations Act as registered holder pursuant to the issue of such shares by Mesoblast Limited to Cephalon International Holdings, Inc. in accordance with the strategic alliance described in the ASX announcement issued by Mesoblast Limited on 8 December 2010, as approved by Mesoblast Limited shareholders on 9 February 2011.	\$4.35 per ordinary share	24,702,056 ordinary shares	24,702,056
11 February 2	O11 Cephalon, Inc.	Relevant interest under section 608(3)(b) of the Corporations Act	Not applicable	24,702,056 ordinary shares	24,702,056
11 February 2	011 Cephalon related bodies corporate	Relevant interest under section 608(3)(a) of the Corporations Act	Not applicable	24,702,056 ordinary shares	24,702,056

## 4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Cephalon International Holdings, Inc.	Cephalon International Holdings, Inc.	Not applicable	Relevant interest under section 608(1)(a) of the Corporations Act.	55,785,806 ordinary shares	55,785,806
Cephalon, Inc.	Cephalon International Holdings, Inc.	Not applicable	Relevant interest under section 608(3)(b) of the Corporations Act.	55,785,806 ordinary shares	55,785,806
Cephalon related bodies corporate	Cephalon International Holdings, Inc.	Not applicable	Relevant interest under section 608(3)(a) of the Corporations Act.	55,785,806 ordinary shares	55,785,806

# 5. Changes in association

The persons who have become associates of, ceased to be associates (2) of, or have changed the nature of their association with (9), the substantial holder in relation to voting interests in the company or scheme are as follows:

	·
Name and ACN/ARSN (If applicable)	Nature of association
Not applicable	Not applicable

## 6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Cephalon International Holdings, Inc.,	41 Moores Road
Cephalon, Inc. and the Cephalon related bodies	Frazer PA 19355
corporate	United States of America

Signature

print name

J. Kevin Buchi by his attorney Timothy Bowley

capacity Under power of attorney

sign here

date

15 February 2011

#### **DIRECTIONS**

To: 01300135638#193

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of
  - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (e.g. if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

This is Annexure A of 1 page referred to in the Form 604 (Notice of change of interests of substantial holder) signed by me and dated 15 February 2011.

J. Kevin Buchi by his attorney Timothy Bowley

# **ANNEXURE A**

Anesta LLC

Anesta AG

Arana Therapeutics, Inc.

**BioAssets Development Corporation** 

Biotan AG

Cephalon Australia Pty. Ltd. ACN 002 951 877

Cephalon Australia (Vic) Pty. Ltd. ACN 097 483 068

Cephalon (Bermuda) Limited

Cephalon Boringuen, Inc.

Cephalon B.V.

Cephalon Clinical Partners L.P.

Cephalon Development Corporation

Cephalon France SAS

Cephalon Europe SAS

Cephalon GmbH

Cephalon Holdings Limited

Cephalon Investments, Inc.

Cephalon Italia S.r.L

Cephalon Limited

Cephalon Luxembourg S.a.r.l

Cephalon Management Company LLC

Cephalon Management Company LUX SCS

Cephalon Pharma ApS

Cephalon Pharma (Ireland) Limited

Cephalon Pharma SL

Cephalon Sp.z.o.o.

Cephalon Technologies Partners, Inc.

Cephalon Technology, Inc.

Cephalon Titrisation

Cephalon (UK) Limited

Cephalon Ventures Puerto Rico, Inc.

CIMA LABS INC.

East End Insurance Ltd.

Galenis-Promoção e Comercialização de Products Farmacêuticos LDA

Mepha GmbH

MEPHA-Investigação, Desenvolvimento e Fabricação Farmacêutical LDA

Mepha (Latino-Americana) S.A.

Mepha Pharma AG

Mepha Pharma GMBH

Mepha Pharma India Private Limited

PolaRx Biopharmaceuticals, Inc.

Promics Pty. Ltd. ACN 089 138 063

SIA Mepha Baltics

Societe Civile Immobiliere Martigny

Zeneus Pharma S.a.r.l.